Safety and preliminary efficacy of hemoglobin raffimer for patients undergoing coronary artery bypass surgery

Steven E. Hill, Lewis I. Gottschalk, Katherine Grichnik

Research output: Contribution to journalArticlepeer-review

49 Scopus citations


Objective: To evaluate the safety and preliminary efficacy of escalating doses of hemoglobin raffimer (Hemolink) with intraoperative autologous blood donation for coronary artery bypass graft (CABG) surgery. Design: Randomized, controlled, single-blind phase II dose escalation trial. Setting: Multi-institutional university setting. Participants: Adult patients (n = 60) undergoing elective CABG surgery. Interventions: After induction of anesthesia, autologous whole blood was collected to achieve a hemoglobin of 7 g/dL on cardiopulmonary bypass. Patients were randomized to receive either hemoglobin raffimer (treatment) or 6% hetastarch (control}) in sequential escalating dose blocks of 250 mL, 500 mL, or 750 mL. After return of autologous blood, allogeneic red blood cells were transfused according to predetermined hemoglobin triggers. Measurements and Main Results: Safety parameters (vital signs, hematology, blood chemistry, coagulation, and adverse events) were monitored from randomization through week 4 postdischarge. Serious adverse events were distributed evenly between the 2 groups of patients. Elevated blood pressure was more frequent in the treatment group (16/28 mmHg v 9/32 mmHg, p = 0.036), In the group of 40 patients in the 750-mL dose block, 8 of the 18 treatment patients and 4 of the 22 control patients avoided allogeneic red blood cell transfusion (p = 0.093). Median volume of allogeneic red blood cells transfused was lower in treated subjects compared with controls (p = 0.042). Conclusion: Hemoglobin raffimer is well tolerated and may be effective in reducing transfusion for patients undergoing CABG surgery. Although perioperative hypertension was more frequent in the treated patients, blood pressure management prevented serious adverse sequelae. Definitive evaluation of efficacy in a larger phase III trial is warranted.

Original languageEnglish (US)
Pages (from-to)695-702
Number of pages8
JournalJournal of cardiothoracic and vascular anesthesia
Issue number6
StatePublished - Dec 2002


  • Cardiac surgery
  • Hemoglobin-based oxygen carriers
  • Intraoperative autologous donation (lAD), hemoglobin raffimer
  • Oxygen therapeutic agents

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Anesthesiology and Pain Medicine


Dive into the research topics of 'Safety and preliminary efficacy of hemoglobin raffimer for patients undergoing coronary artery bypass surgery'. Together they form a unique fingerprint.

Cite this